Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM2 | Q9P1W9 | 10/20 | 0.74 |
| ▸ | PIM1 | P11309 | 9/20 | 0.74 |
| ▸ | PIM3 | Q86V86 | 9/20 | 0.74 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | TTR | P02766 | 3/20 | 0.58 |
| ▸ | NAT1 | P18440 | 1/20 | 0.55 |
| ▸ | IGF1R | P08069 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 2/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | TDP2 | O95551 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | CASP9 | P55211 | 1/20 | 0.50 |
| ▸ | CASP6 | P55212 | 1/20 | 0.50 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1579417 | 1.00 | PIM2 (0.74) | PIM2PIM1PIM3MEN1KMT2A | |
| SCHEMBL1579117 | 1.00 | PIM2 (0.74) | PIM2PIM1PIM3MEN1KMT2A | |
| Water SCHEMBL6293323 | 0.99 | PIM2 (0.73) | PIM2PIM1PIM3MEN1KMT2A | |
| Water SCHEMBL6293321 | 0.99 | PIM2 (0.73) | PIM2PIM1PIM3MEN1KMT2A | |
| Water SCHEMBL6293322 | 0.99 | PIM2 (0.73) | PIM2PIM1PIM3MEN1KMT2A | |
| SCHEMBL13537656 | 0.88 | PIM1 (0.80) | PIM2PIM1PIM3MEN1KMT2A | |
| SCHEMBL10090250 | 0.87 | NAT1 (0.60) | PIM2PIM1PIM3MEN1KMT2A | |
| SCHEMBL2065290 | 0.87 | NAT1 (0.60) | PIM2PIM1PIM3MEN1KMT2A | |
| SCHEMBL2065291 | 0.87 | NAT1 (0.60) | PIM2PIM1PIM3MEN1KMT2A | |
| SCHEMBL2420571 | 0.86 | PIM2 (0.70) | PIM2PIM1PIM3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007026219-A2 | COMBINATIONS OF A 5-HT1B ANTAGONIST WITH A NORADRENALIN RE-UPTAKE INHIBITOR OR A SEROTONIN NORADRENALIN REUTAKE INHIBITOR FOR TREATING CNS CONDITIONS | PFIZER PRODUCTS INC. (US) | 2007-03-08 | — | — | WO | claimed |
| US-6403592-B1 | SEROTONIN REUPTAKE INHIBITORS | PFIZER INC | 2002-06-11 | — | — | US | claimed |
| US-20020049211-A1 | Combination treatment for depression and anxiety | SOBOLOV-JAYNES SUSAN BETH (US) | 2002-04-25 | — | — | US | claimed |
| EP-1186318-A2 | Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | claimed |
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| WO-2007026219-A2 | COMBINATIONS OF A 5-HT1B ANTAGONIST WITH A NORADRENALIN RE-UPTAKE INHIBITOR OR A SEROTONIN NORADRENALIN REUTAKE INHIBITOR FOR TREATING CNS CONDITIONS | PFIZER PRODUCTS INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20060052373-A1 | Combination of dopamine agonists and aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC | 2006-03-09 | — | — | US | disclosed |
| EP-1562908-A1 | QUINOLINE DERIVATIVES | Pfizer Products Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| US-6921760-B2 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC. (US) | 2005-07-26 | — | — | US | disclosed |
| WO-2005053701-A1 | COMBINATION OF DOPAMINE AGONISTS AND ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER PRODUCTS INC. (US) | 2005-06-16 | — | — | WO | disclosed |
| US-6894062-B1 | Quinoline derivatives | PFIZER INC. (US) | 2005-05-17 | — | — | US | disclosed |
| WO-2004043929-A1 | QUINOLINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2002046167-A1 | BENZYL (IDENE)-LACTAMS AND THEIR USE AS 5HT1-RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| US-6403592-B1 | SEROTONIN REUPTAKE INHIBITORS | PFIZER INC | 2002-06-11 | — | — | US | disclosed |
| US-6380186-B1 | PSYCHOTHERAPEUTIC AGENTS | PFIZER INC | 2002-04-30 | — | — | US | disclosed |
| US-20020049211-A1 | Combination treatment for depression and anxiety | SOBOLOV-JAYNES SUSAN BETH (US) | 2002-04-25 | — | — | US | disclosed |
| US-20020049214-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER PRODUCTS INC. | 2002-04-25 | — | — | US | disclosed |
| EP-1186318-A2 | Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| EP-0929528-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. (US) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998014433-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. (US) | 1998-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049214-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | PIM2 620/4885PIM1 871/4885PIM3 806/4885 |
| US-20060052373-A1 | Combination of dopamine agonists and aralkyl and aralkylidene heterocyclic lactams and imides | DRD2, OPRL1, SLC6A3 | PIM2 1745/4885PIM1 2149/4885PIM3 1703/4885 |
| US-20020049211-A1 | Combination treatment for depression and anxiety | HTR1A, HTR1D, HTR5A | PIM2 4670/4885PIM1 3799/4885PIM3 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.